Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC 

Reporting from ESMO Congress 2023 in Madrid, Nicolas Girard discusses the results from two important studies on amivantamab in combination therapy for first-line treatment of patients with EGFR-mutated, advanced NSCLC
Abstracts discussed:
LBA14 - Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial, presented by B.C. Cho
LBA5 - Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global Study, presented by Nicolas Girard
Simultaneous publication in the NEJM: www.nejm.org/d...
Produced by the European Society for Medical Oncology
oncologypro.es...